Palisade Bio, Inc. (PALI)
| Market Cap | 337.36M +9,996.2% |
| Revenue (ttm) | n/a |
| Net Income | -24.15M |
| EPS | -0.23 |
| Shares Out | 167.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,220,743 |
| Open | 2.010 |
| Previous Close | 2.010 |
| Day's Range | 1.960 - 2.068 |
| 52-Week Range | 0.530 - 2.855 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 9.71 (+381.89%) |
| Earnings Date | May 12, 2026 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price target is $9.71, which is an increase of 381.89% from the latest price.
News
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Palisade Bio files $300M mixed securities shelf
17:28 EDT Palisade Bio (PALI) files $300M mixed securities shelf
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance she...
Palisade Bio Registration statement: Registration filing
Palisade Bio filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Palisade Bio Quarterly report: Q1 2026
Palisade Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
Palisade Bio Earnings release: Q1 2026
Palisade Bio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel oral PDE4 inhibitor prodrug for IBD showed strong early efficacy and safety in UC and Crohn's, with 100% response in a UC phase Ib and robust PK/PD in Crohn's. Phase II trials are set for 2024, supported by $135M in cash and a precision medicine approach.
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biop...
Palisade Bio initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of Palisade Bio (PALI) with an Outperform rating and $7 price target The firm sees a “quiet 2026,” but is bullish into ulcerative…
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Compa...
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street
Clear Street keeps a Buy rating and $12 price target on Palisade Bio (PALI), saying the decline in the stock price after the Phase 1B Clinical Study of PALI-2108 in…
Palisade Bio Transcript: Study result
Phase I-B data for PALI-2108 in fibrostenotic Crohn's disease showed strong safety, robust PK/PD, and early clinical activity, with 40% endoscopic response/remission in a refractory population. Once-daily oral dosing and dual anti-inflammatory/anti-fibrotic action support further development in broader Crohn's cohorts.
Palisade Bio Press release: Study result
Palisade Bio issued a press release on March 31, 2026, disclosing material business information to investors.
Palisade Bio Slides: Study result
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
Palisade Bio announces topline data from PALI-2108 trial
Palisade Bio (PALI) announced topline data from its Phase 1b clinical study evaluating PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colo...
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement...
Palisade Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Palisade Bio (PALI) with a Buy rating and $7 price target The firm thinks investors are looking at PALI-2108 “through the lens of older-generation, systemic…
Palisade Bio Annual report: Q4 2025
Palisade Bio has published its Q4 2025 annual report on March 20, 2026.
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference
PALI-2108, a locally activated PDE4 inhibitor prodrug, is advancing in IBD with strong early efficacy and safety data, a dual anti-inflammatory/anti-fibrotic mechanism, and a robust financial runway. Key clinical milestones are set for 2024–2028, with strategic flexibility in Crohn's indications.